
0:00
7:00
It's a quiet week for dedicated acromegaly research — no top-tier-journal hits, just a pasireotide cost-effectiveness review and a giant-adenoma case report — while the wider rare disease industry absorbed a surprise Phase 3 failure in the ATTR-CM heart drug market and a fresh round of White House drug-pricing deals touching major rare-disease manufacturers.
More episodes from "Acromegaly Update"



Don't miss an episode of “Acromegaly Update” and subscribe to it in the GetPodcast app.








